Last reviewed · How we verify
VIR-3434
At a glance
| Generic name | VIR-3434 |
|---|---|
| Also known as | Tobevibart, tobevibart, BRII-877 |
| Sponsor | Vir Biotechnology, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (PHASE3)
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (PHASE1, PHASE2)
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection (PHASE2)
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection (PHASE3)
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (PHASE2)
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. (PHASE2)
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 (PHASE1)
- Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIR-3434 CI brief — competitive landscape report
- VIR-3434 updates RSS · CI watch RSS
- Vir Biotechnology, Inc. portfolio CI